The biotech market offers great investment potential due to innovative advancements in genetic profiling, biologics, CRISPR ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to ...

Pharma dealmaking for drugs invented in China is putting pressure on U.S. biotechs to compete harder, according to investors ...

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.

The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

Similar trends have been observed for companies that manufacture tools for production in the pharmaceutical and biotech ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

"Real-time analytics is more than just a tool—it’s a paradigm shift," says Dr. Aditya Dodda, an expert in building real-time ...

BMO Capital analyst Kostas Biliouris has maintained their bullish stance on LEGN stock, giving a Buy rating yesterday.Invest with Confidence: ...